Celltrion: Celltrion wins Korea approval for Phase 3 trial of CTP13 SC (Zymfentra)
AI reading
★★★★ Bullish · Material event
Korea clears Phase 3 trial of Zymfentra
An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).
Other filings by Celltrion
- 10.12 ★★★ Q3 revenue and operating profit rise from prior quarter and year earlier
- 09.23 ★★★ Celltrion: FDA clears Phase 3 trial for Zymfentra in rheumatoid arthritis
- 09.23 ★★ Files report on major shareholding
- 09.21 ★★★ Celltrion: EMA clears Phase 3 trial for Darzalex biosimilar
- 09.16 ★★ Company announces share retirement to boost shareholder value
- 09.07 ★★★ Celltrion: FDA approves amended Phase 3 trial plan for Keytruda biosimilar
For information only. Not investment advice.